|Bid||4.00 x 3100|
|Ask||4.65 x 800|
|Day's Range||4.42 - 5.26|
|52 Week Range||3.48 - 40.66|
|Beta (5Y Monthly)||2.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2022 - Mar 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.57|
NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), presented at the 8th Congress of the European Academy of Neurology (EAN). Links to the presentations are included below. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We a
Valneva SE Sponsored ADR (VALN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...